联盟
标准化
人类血液
血小板
血液制品
输血医学
业务
生产(经济)
利润(经济学)
医学
输血
免疫学
政治学
经济
法学
外科
生理学
宏观经济学
微观经济学
作者
Dirk de Korte,Willem Delabie,Hendrik B. Feys,Thomas R. Klei,Rune Larsen,Ólafur E. Sigurjónsson,Ana Paula Sousa
摘要
Abstract Human platelet lysate (hPL) is a supplement for cell culture media that can be derived from platelet concentrates. As not‐for‐profit blood establishments, we endorse the evolution of maximally exploiting the potential of donated blood and its derived components, including platelets. The decision to use platelet concentrates to supply hPL as a cell culture supplement should align with the principles and values that blood establishments hold towards the use of donated blood components in transfusion. As a consequence, questions on ethics, practical standardization of hPL production and logistics as well as on assuring hPL quality and safety need careful consideration. We therefore propose an opinion on some of these matters based on available literature and on discussions within the proceedings of the Working Group on Innovation and New Products of the European Blood Alliance. In addition, we propose collaboration among European blood establishments to streamline efforts of hPL supply to maximize the potential of hPL and its application in the wider field of medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI